Akèy › Skizofreni › Illinois
Etid klinik pou Skizofreni nan Illinois
25 etid pou Skizofreni ap chèche patisipan nan sit nan Illinois.
Vil nan Illinois
Tèks ofisyèl etid la (Anglè)
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Evanston Hospital, Evanston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07101094A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Uptown Research Institute, Chicago
Ap rekriteFaz 1
Laj 18 a 55 · Tout sèks · Mizajou Sep 28, 2026 · NCT07615426Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0067, Chicago
- Pillar Clinical Research -Chicago, Chicago
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 28, 2026 · NCT07686263NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
- Neurocrine Clinical Site, Oak Brook
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 25, 2026 · NCT07114874Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Baber Research Group, Naperville
Ap rekriteFaz 3
Laj 5 a 17 · Tout sèks · Mizajou Sep 25, 2026 · NCT06229210A Study of Brenipatide in Adult Participants With Schizophrenia
- Re:Cognition Health - Chicago, Chicago
Ap rekriteFaz 2
Laj 18 a 55 · Tout sèks · Mizajou Sep 22, 2026 · NCT07410507A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Local Institution - 0175, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
Ap rekriteFaz 3
Laj 5 a 17 · Tout sèks · Mizajou Sep 22, 2026 · NCT07424404A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Naperville
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT0710511152-week Open Label Safety-Tolerability Study
- Pillar Clinical Research, Chicago
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 9, 2026 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Local Institution - 0122, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
Ap rekriteFaz 3
Laj 13 a 17 · Tout sèks · Mizajou Sep 4, 2026 · NCT07288567A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
- Uptown Research Institute, Chicago
Ap rekriteFaz 1
Laj 18 a 55 · Tout sèks · Mizajou Sep 2, 2026 · NCT07061288A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Chicago
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 1, 2026 · NCT07459647Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0046, Crystal Lake
- Amr Conventions Research - Illinois, Warrenville
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT07379827Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Chicago
Ap rekriteFaz 3
Laj 10 a 17 · Tout sèks · Mizajou Aug 14, 2026 · NCT05303064Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
- Uptown Research Institute LLC, Chicago
- Pillar Clinical Research LLC, Chicago
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Jul 29, 2026 · NCT07467993Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Pillar Clinical Research, Chicago
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Jul 27, 2026 · NCT07363577Transition Care for FEP
- University of Chicago Ingalls Memorial Hospital, Harvey
Ap rekriteEtid obsèvasyon
Laj 18 a 40 · Tout sèks · Mizajou Jul 20, 2026 · NCT07713849A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Uptown Research Institute, Chicago
Ap rekriteFaz 2
Laj 18 a 55 · Tout sèks · Mizajou Jun 23, 2026 · NCT07191483A Study to Evaluate the Effect of KarXT on Urological Safety
- Uptown Research Institute, Chicago
- Pillar Clinical Research -Chicago, Chicago
Ap rekriteFaz 4
Laj 18 a 65 · Tout sèks · Mizajou Jun 3, 2026 · NCT07221877CLOZAPINE Response in Biotype-1
- University of Chicago, Chicago
Ap rekriteFaz 4
Laj 18 a 60 · Tout sèks · Mizajou May 11, 2026 · NCT04580134Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Chicago Medical Center, Chicago
Ap rekriteEtid obsèvasyon
Laj 18 a 40 · Tout sèks · Mizajou Mar 10, 2026 · NCT06740383NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Mar 6, 2026 · NCT06963034Randomized Withdrawal Study in Patients With Schizophrenia
- Vanda Investigational Site, Chicago
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Jan 12, 2026 · NCT06961968Study of ALTO-101 in Patients With Schizophrenia
- Site 5056, Chicago
Ap rekriteFaz 2
Laj 21 a 55 · Tout sèks · Mizajou Dec 26, 2025 · NCT06502964Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Chicago
Ap rekriteFaz 3Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Dec 19, 2024 · NCT05184335Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.